177Lu-DOTATATE 受体放射性核素治疗在 Ki-67 增殖指数高的胃肠胰神经内分泌肿瘤患者中的研究
本研究纳入 33 例晚期胃肠胰神经内分泌肿瘤(GEP-NEN)、生长抑素受体显像阳性(SRI+)且 Ki-67 指数 15%–70% 的患者,接受 177Lu-DOTATATE 肽受体放射性核素治疗(PRRT),累计活度 18.5 GBq 或 27.8 GBq,分 4 或 5 个周期。结果显示疾病控制率(DCR)70%,中位无进展生存期(PFS)23 个月,中位总生存期 52.9 个月;Ki-67 ≤35% 组 DCR 87%、中位 PFS 26.3 个月,均优于 Ki-67 36–70% 组的 30% 和 6.8 个月(p=0.005)。作者认为 PRRT 应作为高分级 SRI+ GEP-NEN 的治疗选择,尤其是 Ki-67 ≤35% 者。
要点
- 33 例 SRI+ 晚期 GEP-NEN(Ki-67 15%–70%)接受 177Lu-DOTATATE PRRT,DCR 70%,中位 PFS 23 个月。
- Ki-67 ≤35% 组 DCR 87%、中位 PFS 26.3 个月,优于 Ki-67 36–70% 组的 30% 和 6.8 个月(p=0.005)。
- 作者认为高分级 SRI+ GEP-NEN 可考虑 PRRT,尤其 Ki-67 ≤35% 者。
核心结论
- Lu-PRRT 在 SRI+ 的中分级和高分级 GEP-NEN 中显示抗肿瘤活性。
- Ki-67 ≤35% 患者的 DCR 和 PFS 显著优于 Ki-67 >35% 患者。
- 作者认为,基于上述结果,PRRT 应被视为高分级 SRI+ GEP-NEN 的治疗选择,尤其是 Ki-67 ≤35% 者。
研究设计与样本
- 研究纳入 33 例晚期 GEP-NEN、生长抑素受体显像阳性(SRI+)且 Ki-67 增殖指数 15%–70% 的患者。
- 患者接受 177Lu-DOTATATE 肽受体放射性核素治疗(PRRT),累计活度 18.5 GBq 或 27.8 GBq,分 4 或 5 个周期给药。
- 采用受试者工作特征(ROC)曲线分析确定预测疾病进展的最佳 Ki-67 阈值。
主要发现
- 所有患者均完成预定治疗,中位随访 43 个月(范围 3–69 个月)。
- 2 例(6%)达到部分缓解,21 例(64%)疾病稳定,疾病控制率(DCR)为 70%。
- 中位无进展生存期(PFS)为 23 个月(95%CI 14.9–31.0 个月),中位总生存期为 52.9 个月(95%CI 17.1–68.9 个月)。
- 23 个月时 ROC 曲线分析显示最佳 Ki-67 阈值为 35%;Ki-67 ≤35% 组 23 例(70%),Ki-67 36–70% 组 10 例(30%)。
- Ki-67 ≤35% 组 DCR 为 87%,Ki-67 36–70% 组为 30%;中位 PFS 分别为 26.3 个月(95%CI 18.4–37.7 个月)和 6.8 个月(95%CI 2.1–27 个月),p=0.005。
关键数值与推荐
- 2010 年 WHO 分类以 Ki-67 增殖指数 20% 作为中级别与高级别胃肠胰神经内分泌肿瘤(GEP-NEN)的分界值。
- 临床实践中,Ki-67 指数 >15% 的肿瘤常被视为高分级并接受化疗。
- 40%–70% 的高分级 NEN 过表达生长抑素受体,使肽受体放射性核素治疗(PRRT)得以实施。
- Ki-67 ≤35% 组与 36–70% 组的 DCR 分别为 87% 和 30%,中位 PFS 分别为 26.3 个月和 6.8 个月(p=0.005)。
临床怎么用
- 作者认为,基于本研究结果,PRRT 应被视为高分级 SRI+ GEP-NEN 的治疗选择,尤其是 Ki-67 ≤35% 者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In the 2010 WHO classification, a Ki-67 proliferation index of 20% is the cut-off between intermediate-grade and high-grade gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN). However, in clinical practice, tumours with a Ki-67 index of >15% are often considered high grade and treated with chemotherapy. In 40-70% of high-grade NENs, somatostatin receptors are overexpressed, enabling peptide receptor radionuclide therapy (PRRT) to be performed. We investigated the role of PRRT with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index. METHODS: A total of 33 patients with advanced GEP-NENs, positive somatostatin receptor imaging (SRI+) and a Ki-67 proliferation index ranging from 15% to 70% were treated with Lu-PRRT. A cumulative activity of 18.5 GBq or 27.8 GBq of 177Lu-DOTATATE was administered in four or five cycles. Receiver operating characteristic (ROC) curve analysis was used to determine the best threshold of Ki-67 expression to predict disease progression. RESULTS: All patients completed the intended treatment. The median follow-up was 43 months (range 3-69 months). Two patients (6%) achieved a partial response and 21 (64%) showed stable disease, giving a disease control rate (DCR) of 70%. The median progression-free survival (PFS) was 23 months (95% CI 14.9-31.0 months) and the median overall survival was 52.9 months (95% CI 17.1-68.9 months). ROC curve analysis at 23 months revealed that the best Ki-67 index cut-off was 35%. In 23 patients (70%) the Ki-67 index was ≤35% and in 10 patients (30%) the Ki-67 index was in the range 36-70%. The DCR in the former group was 87% and 30% in the latter. The median PFS was 26.3 months (95% CI 18.4-37.7 months) and 6.8 months (95% CI 2.1-27 months), respectively (p = 0.005). CONCLUSIONS: Lu-PRRT showed antitumour activity in SRI+ GEP-NENs of intermediate and high-grade. DCR and PFS were significantly better in patients with a Ki-67 index of ≤35% than in those with a Ki-67 index of >35%. On the basis of these results, PRRT should be considered as a therapeutic option in patients with high-grade SRI+ GEP-NENs, in particular those with a Ki-67 proliferation index of ≤35%.
引用
- Nicolini S, Severi S, Ianniello A, et al. Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index. Eur J Nucl Med Mol Imaging. 2018. PMID: 29387927. doi:10.1007/s00259-017-3925-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。